|
lupus nephritis |
20 |
|
outcomes |
14 |
|
chronic kidney disease |
13 |
|
dialysis |
13 |
|
hepatitis b |
13 |
|
kidney transplantation |
13 |
|
systemic lupus erythematosus |
13 |
|
humans |
10 |
|
male |
9 |
|
middle aged |
9 |
|
peritoneal dialysis |
9 |
|
risk factors |
9 |
|
acute kidney injury |
8 |
|
adult |
8 |
|
antiviral |
8 |
|
covid-19 |
8 |
|
entecavir |
8 |
|
epidemiology |
8 |
|
female |
8 |
|
hbv |
8 |
|
hepatitis b vaccination |
8 |
|
intradermal |
8 |
|
model |
8 |
|
nephrotoxicity |
8 |
|
nucleoside analogues |
8 |
|
prediction |
8 |
|
risk assessment |
8 |
|
sodium |
8 |
|
tenofovir |
8 |
|
tlr7 agonist |
8 |
|
advanced cirrhosis |
7 |
|
biomarkers |
7 |
|
hepatorenal syndrome |
7 |
|
peritonitis |
7 |
|
pharmacokinetics |
7 |
|
prognosis |
7 |
|
proteinuria |
7 |
|
aged |
6 |
|
kidney |
6 |
|
kidney failure, chronic - therapy |
6 |
|
long-term |
6 |
|
lupus |
6 |
|
nephritis |
6 |
|
pathogenesis |
6 |
|
renal failure |
6 |
|
renal transplantation |
6 |
|
transplantation |
6 |
|
acute exacerbation |
5 |
|
atrial fibrillation |
5 |
|
chronic obstructive pulmonary disease |
5 |
|
direct oral anticoagulant |
5 |
|
estimated glomerular filtration rate |
5 |
|
hypernatraemia |
5 |
|
ischemic stroke |
5 |
|
medical sciences |
5 |
|
mycophenolate mofetil |
5 |
|
mycophenolic acid |
5 |
|
nephrotic syndrome |
5 |
|
outcome |
5 |
|
renal dysfunction |
5 |
|
renal function variability |
5 |
|
subsets |
5 |
|
treatment |
5 |
|
urology and nephrology |
5 |
|
valvular heart disease |
5 |
|
warfarin |
5 |
|
adenine - analogs and derivatives - therapeutic use |
4 |
|
aged, 80 and over |
4 |
|
angiography - adverse effects - economics - methods |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
antiviral agents - adverse effects - therapeutic use |
4 |
|
b cells |
4 |
|
biopsy |
4 |
|
catheterization, central venous - instrumentation |
4 |
|
catheters, indwelling |
4 |
|
chronic renal disease |
4 |
|
complication |
4 |
|
conventional arteriogram |
4 |
|
cost |
4 |
|
ct angiogram |
4 |
|
drug resistance, multiple, bacterial |
4 |
|
end stage renal disease |
4 |
|
fever - etiology |
4 |
|
follow-up studies |
4 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - mortality |
4 |
|
herpes zoster |
4 |
|
hong kong - epidemiology |
4 |
|
hyaluronan |
4 |
|
incidence |
4 |
|
infection |
4 |
|
influenza |
4 |
|
intercellular adhesion molecule-1 |
4 |
|
invasive pneumococcal disease |
4 |
|
kidney diseases - complications - surgery |
4 |
|
kidney neoplasms - pathology |
4 |
|
kidney transplantation - adverse effects - mortality |
4 |
|
lamivudine |
4 |
|
living donors |
4 |
|
living kidney donor |
4 |
|
ln |
4 |
|
lymphoma - pathology |
4 |
|
malnutrition - etiology |
4 |
|
peritoneal dialysis - adverse effects |
4 |
|
peritonitis - drug therapy - epidemiology - microbiology |
4 |
|
portal vein - radiography |
4 |
|
progressive outer retinal necrosis |
4 |
|
proteinuria - etiology |
4 |
|
renal dialysis - adverse effects |
4 |
|
renal dialysis - instrumentation - methods |
4 |
|
renin inhibitor |
4 |
|
resistance |
4 |
|
retrospective studies |
4 |
|
sirolimus |
4 |
|
streptococcal infections - epidemiology - microbiology |
4 |
|
streptococcus bovis |
4 |
|
streptococcus bovis - isolation & purification |
4 |
|
superior mesenteric artery syndrome |
4 |
|
superior mesenteric artery syndrome - etiology - radiography - therapy |
4 |
|
survival rate - trends |
4 |
|
syndecan-1 |
4 |
|
tacrolimus |
4 |
|
thrombomodulin |
4 |
|
time factors |
4 |
|
tomography, x-ray computed - adverse effects - economics - methods |
4 |
|
varicella zoster virus |
4 |
|
vascular anomalies |
4 |
|
vascular cell adhesion molecule-1 |
4 |
|
vascular neoplasms - pathology |
4 |
|
abo incompatibility |
3 |
|
adenine - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
aki |
3 |
|
alanine transaminase - blood |
3 |
|
allograft |
3 |
|
anti-dsdna antibodies |
3 |
|
antiphospholipid antibodies |
3 |
|
antiviral agents - therapeutic use |
3 |
|
apolipoprotein e |
3 |
|
b cell depletion |
3 |
|
b cell signatures |
3 |
|
burkholderia cepacia |
3 |
|
cardiovascular |
3 |
|
chinese |
3 |
|
chronic allograft nephropathy |
3 |
|
chronotropic incompetence |
3 |
|
commencement |
3 |
|
cpra |
3 |
|
creatinine - metabolism |
3 |
|
cyclophosphamide |
3 |
|
cytokines |
3 |
|
direct renin inhibitor |
3 |
|
disease relapse |
3 |
|
dna, viral - analysis |
3 |
|
dose-response relationship, drug |
3 |
|
drug resistance, viral |
3 |
|
emerging therapies |
3 |
|
exercise tolerance |
3 |
|
exit-site infection |
3 |
|
gram-negative bacterial infections - diagnosis - etiology - therapy |
3 |
|
gram-positive bacterial infections - diagnosis - etiology - therapy |
3 |
|
guanine - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
hepatitis b - complications - drug therapy |
3 |
|
hla sensitization |
3 |
|
hyponatremia |
3 |
|
hysteroscopy - adverse effects |
3 |
|
iga nephropathy |
3 |
|
immunoglobulin g |
3 |
|
immunoglobulins |
3 |
|
immunosuppressive agents |
3 |
|
inflammation |
3 |
|
kidney - drug effects |
3 |
|
lamivudine - therapeutic use |
3 |
|
lamivudine resistance |
3 |
|
lipoprotein glomerulopathy |
3 |
|
long term |
3 |
|
lupus nephritis pathogenesis |
3 |
|
minimal change disease |
3 |
|
mitogen-activated protein kinase (mapk) |
3 |
|
mycophenolate |
3 |
|
nephropathy |
3 |
|
organ allocation |
3 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
3 |
|
peritonitis - microbiology |
3 |
|
phosphonic acids - pharmacology - therapeutic use |
3 |
|
plasma renin activity |
3 |
|
proximal renal tubular epithelial cells |
3 |
|
psychological symptoms |
3 |
|
renal allograft recipient |
3 |
|
renal palliative care |
3 |
|
serum cytokines |
3 |
|
shear wave elastography |
3 |
|
sle |
3 |
|
sleep apnea |
3 |
|
statin |
3 |
|
ultrasound |
3 |
|
viral load - drug effects |
3 |
|
virtual crossmatch |
3 |
|
acinetobacter |
2 |
|
acute disease |
2 |
|
advanced ckd |
2 |
|
alopecia - etiology |
2 |
|
alternative pathway |
2 |
|
anaemia |
2 |
|
animals |
2 |
|
antiparasitic agents - administration & dosage |
2 |
|
anxiety |
2 |
|
asia |
2 |
|
asymptomatic |
2 |
|
autoantibodies |
2 |
|
azathioprine |
2 |
|
azathioprine - administration & dosage - adverse effects - economics |
2 |
|
b cell abnormalities |
2 |
|
behcet syndrome - complications |
2 |
|
benralizumab |
2 |
|
biopsy, needle |
2 |
|
blys |
2 |
|
carbapenem resistance |
2 |
|
cardiovascular diseases |
2 |
|
caregiver burden |
2 |
|
cause of death |
2 |
|
childhood-onset |
2 |
|
china - epidemiology |
2 |
|
chronic kidney failure |
2 |
|
classical pathway |
2 |
|
clinical outcomes |
2 |
|
complement |
2 |
|
conservative management |
2 |
|
corticosteroids |
2 |
|
cross-sectional studies |
2 |
|
cyclophosphamide - administration & dosage - adverse effects - economics |
2 |
|
cytokines - physiology |
2 |
|
darbepoetin alpha |
2 |
|
delirium |
2 |
|
depression |
2 |
|
diagnosis, differential |
2 |
|
diarrhea - etiology |
2 |
|
diltiazem |
2 |
|
drug costs - statistics & numerical data |
2 |
|
dyslipidaemia |
2 |
|
dyslipidemias - drug therapy - epidemiology - etiology |
2 |
|
emphysema - microbiology - radiography |
2 |
|
end-stage renal failure |
2 |
|
enhanced psychosocial support |
2 |
|
epstein syndrome |
2 |
|
erythropoiesis-stimulating agent |
2 |
|
everolimus |
2 |
|
exit site infection |
2 |
|
extrapulmonary manifestation |
2 |
|
famotidine |
2 |
|
glecaprevir and pibrentasvir |
2 |
|
glomerulonephritis |
2 |
|
glomerulonephritis, iga - complications |
2 |
|
h2 receptor antagonists |
2 |
|
healthy chinese |
2 |
|
hearing loss, sensorineural - diagnosis - genetics |
2 |
|
hemodialysis |
2 |
|
hepatitis b virus |
2 |
|
hepatitis c |
2 |
|
hernia, abdominal - diagnosis - etiology - therapy |
2 |
|
hong kong |
2 |
|
hospital anxiety and depression scale (hads) |
2 |
|
hospital costs - statistics & numerical data |
2 |
|
hydralazine |
2 |
|
hydroxychloroquine |
2 |
|
ifn |
2 |
|
il-17 |
2 |
|
il-18 |
2 |
|
il-6 |
2 |
|
immunocompromised host |
2 |
|
immunology |
2 |
|
immunosuppression |
2 |
|
immunosuppressive agents - administration & dosage - adverse effects - economics |
2 |
|
immunosuppressive agents - adverse effects |
2 |
|
infection - economics - epidemiology - etiology |
2 |
|
ivermectin - administration & dosage |
2 |
|
kaplan-meier estimate |
2 |
|
kidney - microbiology - radiography |
2 |
|
kidney diseases - chemically induced |
2 |
|
kidney failure, chronic - etiology - mortality |
2 |
|
kidney transplantation - adverse effects |
2 |
|
kidney transplantation - methods |
2 |
|
klebsiella infections - radiography |
2 |
|
klebsiella pneumoniae |
2 |
|
lipids - blood |
2 |
|
liver failure |
2 |
|
longterm treatment |
2 |
|
lupus erythematosus, systemic - complications |
2 |
|
lupus erythematosus, systemic - physiopathology |
2 |
|
lupus nephritis - blood - complications |
2 |
|
lupus nephritis - complications - mortality |
2 |
|
lupus nephritis - drug therapy - economics - epidemiology |
2 |
|
lymphocele - diagnosis - etiology - therapy |
2 |
|
lymphocytes |
2 |
|
maintenance immunosuppression |
2 |
|
malignancy |
2 |
|
mammalian target of rapamycin |
2 |
|
mannose-binding lectin pathway |
2 |
|
membranous |
2 |
|
methoxy polyethylene glycol-epoetin beta |
2 |
|
mice |
2 |
|
models, biological |
2 |
|
mortality |
2 |
|
multidrug resistance |
2 |
|
mycophenolic acid - administration & dosage - adverse effects - analogs & derivatives - economics |
2 |
|
myosin heavy chains - genetics |
2 |
|
oral ulcer - etiology |
2 |
|
pain |
2 |
|
pneumonia - economics - epidemiology - etiology |
2 |
|
preemptive treatment |
2 |
|
primary membranous nephropathy |
2 |
|
proliferation signal inhibitor |
2 |
|
psoriasis - diagnosis - drug therapy - parasitology |
2 |
|
pyelonephritis - microbiology - radiography |
2 |
|
quality of life (qol) |
2 |
|
randomized controlled trial (rct) |
2 |
|
recurrence |
2 |
|
relapse |
2 |
|
renal insufficiency |
2 |
|
renal insufficiency - diagnosis - genetics - surgery |
2 |
|
renal survival |
2 |
|
renal transplant |
2 |
|
scabies - diagnosis - drug therapy - parasitology |
2 |
|
scalp dermatoses - diagnosis - drug therapy - parasitology |
2 |
|
serological reactivation |
2 |
|
serratia |
2 |
|
social support |
2 |
|
social worker |
2 |
|
stents |
2 |
|
stevens-johnson syndrome |
2 |
|
symptom |
2 |
|
tacrolimus - adverse effects |
2 |
|
telbivudine |
2 |
|
thrombocytopenia |
2 |
|
thrombocytopenia - diagnosis - genetics |
2 |
|
thrombotic microangiopathy |
2 |
|
tnf |
2 |
|
tomography, x-ray computed |
2 |
|
toxic epidermal necrolysis |
2 |
|
young adult |
2 |
|
acute admission |
1 |
|
advance care planning |
1 |
|
anti-cd20 |
1 |
|
aortic aneurysm |
1 |
|
aortic aneurysm, abdominal - complications - radiography |
1 |
|
aortic rupture - complications - radiography |
1 |
|
asa |
1 |
|
baff |
1 |
|
belimumab |
1 |
|
calcineurin |
1 |
|
charlson co-morbidity index |
1 |
|
childhood-onset lupus nephritis |
1 |
|
clinic |
1 |
|
contamination |
1 |
|
dgcr8 |
1 |
|
diagnosis |
1 |
|
drosha |
1 |
|
emergency department visit |
1 |
|
fall |
1 |
|
fatal outcome |
1 |
|
fracture |
1 |
|
healthcare cost |
1 |
|
hemoperitoneum |
1 |
|
hemoperitoneum - complications - etiology |
1 |
|
hospitalization |
1 |
|
kidney failure, chronic - complications - therapy |
1 |
|
malnutrition |
1 |
|
management |
1 |
|
microrna |
1 |
|
novel |
1 |
|
nursing home older adults |
1 |
|
palliative care |
1 |
|
palliative care follow-up |
1 |
|
pre-bcr |
1 |
|
prevalence |
1 |
|
prophylaxis |
1 |
|
quality improvement |
1 |
|
refractory |
1 |
|
renal impairment |
1 |
|
renal palliative |
1 |
|
rituximab |
1 |
|
umbilical abscess |
1 |
